Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500501 | 0.93 | LTA4H (0.43) | PPARGPPARALTA4HCHRM1TDP1 | |
| SCHEMBL8907429 | 0.89 | ALDH1A1 (0.42) | LTA4HCHRM1SLC6A4ALDH1A1LMNA | |
| SCHEMBL11578028 | 0.89 | ALDH1A1 (0.42) | LTA4HCHRM1SLC6A4ALDH1A1LMNA | |
| SCHEMBL11617114 | 0.89 | ALDH1A1 (0.42) | LTA4HCHRM1SLC6A4ALDH1A1LMNA | |
| SCHEMBL945944 | 0.85 | CHRM1 (0.41) | PPARGPPARALTA4HCHRM1TDP1 | |
| SCHEMBL8888732 | 0.82 | PPARA (0.41) | PPARGPPARASLC6A4 | |
| SCHEMBL8890005 | 0.80 | KMT2A (0.44) | SLC6A4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5092064 | 0.78 | ANPEP (0.41) | CHRM1MTNR1AMTNR1BPOLBLMNA | |
| SCHEMBL626388 | 0.77 | MEN1 (0.42) | PPARGPPARALTA4HCHRM1MTNR1A | |
| SCHEMBL8888223 | 0.75 | MMP13 (0.44) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914222-A | Mixtures comprising herbicides and nitrification inhibitors, such as 2- (3, 4-dimethyl-1H-pyrazol-1-yl) succinic acid (DMPSA) or 3, 4-dimethylpyrazolium glycolate (DMPG) | 巴斯夫欧洲公司 | 2020-03-24 | — | — | CN | claimed |
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-4497738-A | Analogous compounds of cephalosporins, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-02-05 | — | — | US | disclosed |
| EP-0017138-B1 | ANALOGOUS COMPOUNDS OF CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-04 | — | — | EP | disclosed |
| EP-0070575-A2 | New starting compounds for preparing analogous compounds of cephalosporins and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-26 | — | — | EP | disclosed |
| US-4339449-A | Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1982-07-13 | — | — | US | disclosed |
| EP-0017138-A2 | Analogous compounds of cephalosporins, processes for their preparation, and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | PPARG 442/4885PPARA 994/4885LTA4H 1110/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | PPARG 442/4885PPARA 994/4885LTA4H 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.